Product Images Galantamine Hydrobromide

This text provides information about dispensing and storing a medication called Galantamine Oral Solution USP, which contains 4mg of galantamine hydrobromide per 1 mL of aqueous solution. Instructions for proper usage of the container and dispensing-syringe can be found in the accompanying Patient Instructions. The Package Insert should be consulted for complete prescribing information and usual dosage. The solution should be stored at 20°C to 25°C, and not frozen. This medication is distributed by West-Ward Pharmaceuticals Corp. and comes in a 100 mL bottle. The NDC number for this medication is 0054-0137-49. Keep this drug and all others out of the reach of children.*

This appears to be a table or chart with scattered numbers and symbols. It is not clear what this table represents, as the headings or context are missing. Therefore, the description cannot be generated.*

The text seems to indicate a dosage of 24mg/day and a placebo in a study that lasted for four weeks. The remaining text is not readable and appears to be a mix of characters and symbols.*

This is a table that shows the percentage of patients who experienced improvement or worsening of CIBIC-plus rating (a measure of cognitive and functional ability) in relation to different doses of a medication and a placebo. The percentage ranges from 50 to 10, with 50 representing the highest percentage of patients who experienced improvement. The medication was given at 8mg/day, 16mg/day, and 24mg/day respectively. The table also shows the degree of improvement and worsening experienced by the patients.*

This text seems to describe a clinical trial involving a medication called Placebo. The medication is administered at two different dosages, 24mg/day and 32mg/day. The rest of the text seems to be gibberish, likely due to errors in .*

The text provides a graph showing the cumulative percentage of patients with ADAS-cog change from baseline. The graph also shows three points (-10 points, -7 points, and -4 points) where the score worsens. There is a "No Change" category listed as well. The graph compares the effects of placebo with two doses of medication (24 mg/day and 32 mg/day) on ADAS-cog change.*

This appears to be a chart displaying dosages of a medication administered over a period of 13 weeks. The medication appears to have two different dosages, 32 mg/day and 24 mg/day, with a placebo also included. The remaining characters, including special characters such as "¥" and "—", do not provide any additional useful information.*

The given text seems to represent a graph that shows the cumulative percentage of patients with different scores. The scores are marked on the X-axis, such as -10 points, -7 points, -4 points, and no change. Three treatments are compared with each other, which are represented by different lines with labels of Placebo, 24 mg/day, and 32 mg/day. The Y-axis shows the cumulative percentage of patients. The graph also shows the ADAS-cog change from the baseline.*

This appears to be a chart displaying the percentage of patients who showed various levels of improvement after taking different doses of a medication. The medication is not specified and there is not enough context to accurately interpret the chart.*